2,6-Diamino-4,5,6,7-Tetrahydrobenzothiazole

Diastereomeric Resolution of the Racemic Intermediate: Leveraging L‑(+)-Tartaric Acid in Aqueous Methanol

Resolution of (R,S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole into its optical antipodes constitutes the most robust supply‑chain pathway for the dopamine agonist pramipexole dihydrochloride monohydrate. The racemic free base is dissolved in a demineralised water / methanol mixture at a 1:4 volumetric ratio. L‑( + )-tartaric acid is charged at 0.52–0.55 mole equivalents relative to racemate, and the solution is heated under nitrogen to 62–65 °C until complete dissolution. The single diastereomeric salt (S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole hemi‑L‑tartrate crystallises upon controlled cooling to ‑5 °C at a ramp of 5 °C·h⁻¹. After 12 h of ageing at terminal temperature, the crystalline mass is centrifuged on a multi‑stage basket centrifuge, washed with chilled methanol, and dried under vacuum at 45 °C with a nitrogen bleed. Liberation of the (S)-free base with 30 % aqueous NaOH below 20 °C and subsequent acidification with 37 % hydrochloric acid in isopropanol precipitates the API salt. Process non‑conformance arises primarily when the mother liquor content of the undesired (R)-enantiomer exceeds 2.5 % w/w prior to salt removal; this threshold dictates the maximum allowable number of mother‑liquor recycle cycles without chiral purge distillation. The final dried salt routinely meets pharmacopoeial limits: optical purity ≥ 99.5 % ee by chiral HPLC (Chiralpak AD‑H column, 4.6 × 250 mm, hexane / ethanol / diethylamine 90:10:0.1, 0.8 mL·min⁻¹, UV 263 nm), individual specified impurities below 0.10 % per USP 41 monograph, residual methanol ≤ 3000 ppm and isopropanol ≤ 5000 ppm per ICH Q3C. The terminal product, pramipexole dihydrochloride monohydrate, is micronised to D90 ≤ 20 µm for solid oral dosage forms.

What Limits Catalyst Turnover in Ir‑Xyliphos‑Mediated Asymmetric Reductive Amination?

Direct construction of the (S)-N6‑propyl side chain on the tetrahydrobenzothiazole scaffold by metal‑catalysed asymmetric reductive amination bypasses classical salt resolution entirely. The substrate 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole is condensed with propionaldehyde (1.03–1.05 equivalents) in a 2‑methyltetrahydrofuran / tetrafluoropropanol mixture under 10 bar of hydrogen in a Hastelloy‑C autoclave equipped with a hollow‑shaft stirrer (1200 rpm). The catalyst, Ir‑Xyliphos at a substrate‑to‑catalyst molar ratio of 2000:1, generates the desired (S)-enantiomer with ≥ 98.5 % ee and conversion > 99 % within 6–8 h at 70 °C. The process window is narrow: amine‑value titration of the input diamine must confirm purity ≥ 99.0 % and primary amine content consistent with the theoretical 334.5 g·mol⁻¹ equivalent; any cyclic amidine degradation products formed during storage quench the iridium centre irreversibly, depressing turnover number below 1500. Water specification for the input diamine is set at Karl Fischer ≤ 0.05 %, because water‑mediated hydrogenolysis of the imine intermediate generates des‑propyl impurity that co‑elutes with the active pharmaceutical ingredient on polar‑embedded C18 columns (YMC‑Triart C18 ExRS, 150 × 4.6 mm). Post‑reaction, the (S)-free base is isolated by solvent swap to ethyl acetate and crystallisation as the dihydrochloride monohydrate from ethanol / water. All vessels and transfer lines are passivated with citric acid 5 % prior to processing to eliminate extractable nickel, a requirement enforced by ICH Q3D elemental impurity risk assessment for parenteral‑grade active substance. The solid complies with EP 9.0 and ChP 2020 without additional recrystallisation.

Employing 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole as the despropyl precursor in carbon‑11 radiosynthesis mandates selective amine protection that leaves the 6‑position free for acylation with [¹¹C]propionyl chloride. The diamine (0.2 mmol) is stirred with di‑tert‑butyl dicarbonate (0.21 mmol) in anhydrous dichloromethane at 0 °C for 45 min to install a single Boc group on the 2‑amino functionality. The mono‑protected intermediate is purified by flash chromatography on silica‑60 (eluent ethyl acetate / hexane 1:1 with 0.2 % triethylamine) to a chemical purity ≥ 99.5 % and a 6‑position free‑amine assay ≥ 98.0 % by non‑aqueous perchloric acid titration. During the hot‑cell synthesis, the precursor is dissolved in anhydrous acetonitrile and reacted with cyclotron‑produced [¹¹C]propionyl chloride at 35 °C for 5 min. Deprotection with 4 M HCl in dioxane at 60 °C furnishes [¹¹C]pramipexole base. After quenching with ammonium formate buffer pH 6.0 and semi‑preparative HPLC purification (C18 Luna, 10 × 250 mm, 40 % ethanol / 0.1 % formic acid, 4 mL·min⁻¹), the product is sterile‑filtered into a vial containing sodium ascorbate 0.1 % as a radioprotectant. Decay‑corrected radiochemical yield reaches 8–12 % with radiochemical purity ≥ 99 % and molar activity ≥ 80 GBq·µmol⁻¹ at end of synthesis. The entire process is executed under an aseptic cleanroom classification ISO 5, compliant with 21 CFR 212 current good manufacturing practice for positron emission tomography drugs. Release specifications align with Ph. Eur. 09/2013:2485 and USP <823>. The tracer serves as a dopamine D₃ receptor imaging agent for the differential diagnosis of parkinsonian syndromes.

When the Tetrahydrobenzothiazole Core Substitutes 4,4′‑Methylenedianiline in High‑T_g Epoxy Networks

Incorporation of 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole as a tetrafunctional chain extender for diglycidyl ether of bisphenol A (DGEBA, epoxide equivalent weight 188–192 g·eq⁻¹) produces thermosets with elevated glass transition temperatures and reduced moisture uptake compared to traditional aromatic diamines. The heterocyclic thiazole ring contributes a rigid kink that disrupts segmental packing while retaining crosslink density. A stoichiometric gel‑point formulation employs 1.0 mole of the thiazole diamine per 2.0 eq of epoxide, corresponding to a resin‑to‑hardener mass ratio 100:23.5. The diamine is ground and passed through a 200‑mesh sieve, then dispersed into molten DGEBA heated to 80 °C using a planetary mixer (BrePugmill, 30 rpm, 45 min). Degassing under ‑0.95 bar vacuum at 80 °C removes entrapped air before the blend is transferred to a preheated mould. Curing follows a two‑stage ramp: 2 h at 120 °C for linear chain extension, then 3 h at 160 °C for completion of the heterocyclic imidazoline formation that locks the network. Post‑cure analysis by dynamic mechanical analysis (ASTM D7028‑07) in single‑cantilever mode shows a peak loss modulus E″ at 192 °C, which is 40–50 °C higher than conventional m‑phenylenediamine‑cured DGEBA. The equilibrium water absorption after 48 h immersion in boiling water (ASTM D570‑98) falls to 1.2 %, attributed to the hydrophobic character of the thiazole sulphur. Processing latitude is constrained by the diamine’s melting point of 156–158 °C; direct powder incorporation requires a pre‑reaction stage below 90 °C to prevent premature imidazole‑type crosslinking that would elevate viscosity beyond 50 Pa·s and render the compound untoolable for resin transfer moulding. Formulators blending this diamine with bisphenol F epoxies for filament winding should limit pot life to 35 min at 85 °C. The absence of aniline residues renders the cured network eligible for food‑contact certification under EU 10/2011 when migration testing confirms specific migration limits for the diamino monomer below 0.01 mg·kg⁻¹.

Condensation of 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with enantiopure L‑valinol under Mitsunobu conditions affords a conformationally constrained C₁‑symmetric bisoxazoline ligand scaffold used in copper‑catalysed asymmetric Henry reactions. The diamine (10.0 mmol) and L‑valinol (21.0 mmol) are dissolved in dry tetrahydrofuran under argon, cooled to 0 °C, and treated sequentially with triphenylphosphine (24.0 mmol) and diisopropyl azodicarboxylate (24.0 mmol). The mixture warms to ambient temperature over 18 h. The bis‑oxazoline product is isolated by acid‑base extraction and purified by silica‑gel chromatography (dichloromethane / methanol 95:5) to a > 98 % HPLC purity. When this ligand is complexed with Cu(OTf)₂ in isopropanol and applied to the reaction of 4‑nitrobenzaldehyde with nitromethane at ‑20 °C, the (R)-nitroaldol adduct is obtained in 85 % isolated yield with 92 % ee (HPLC, Chiralcel OD‑H). The tetrahydrobenzothiazole core distinguishes this ligand from phenylglycine‑derived C₂‑symmetric bisoxazolines by offering a permanent dipole moment that enhances catalyst solubility in polar aprotic media, enabling catalyst loading as low as 2.5 mol% without erosion of enantioselectivity. Transition‑metal‑leaching tests (ICP‑OES) on the crude product after filtration through a short pad of silica confirm residual copper ≤ 8 ppm. This ligand class has been integrated into pilot‑scale synthesis of adrenergic β‑blocker intermediates where optical purity must exceed 99 % ee prior to hydrochlorination.

Azo Dyestuff Intermediates for Guest‑Host Dichroic Colour Filters

Diazotisation of 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with nitrosyl sulphuric acid at ‑10 to ‑5 °C generates a stable diazonium salt that is coupled to tertiary‑aniline couplers to produce yellow‑to‑orange monoazo dyes exhibiting high order parameters in nematic liquid‑crystal hosts. The diamine (0.1 mol) is dissolved in 85 % phosphoric acid and added dropwise to a pre‑cooled solution of nitrosylsulphuric acid (0.11 mol NO⁺), maintaining a pot temperature no higher than ‑5 °C. The diazo component is then slowly transferred into an ice‑water slurry containing N‑ethyl‑N‑(2‑hydroxyethyl)aniline (0.10 mol) and sodium acetate buffer (pH 4.2). After 3 h of stirring at 0–5 °C, the precipitated dye is collected, washed with deionised water until conductivity < 10 µS·cm⁻¹, and dried in a vacuum tray at 50 °C. The λ_max in N,N‑dimethylformamide is recorded at 438 nm with a molar extinction coefficient ε = 3.2 × 10⁴ L·mol⁻¹·cm⁻¹. When dissolved at 1.0 % w/w in a positive‑dielectric‑anisotropy nematic mixture (Merck E7), the dichroic ratio DR measured in a 10 µm planar cell exceeds 9.2, making it suitable for high‑resolution guest‑host reflective colour filters. Manufacturing under ISO 14001‑certified azo‑dye protocols requires rigorous control of free aromatic amines; batch release testing per § 64 LFGB B 82.02‑2 (EN 14362‑1:2017) must confirm undetectable levels of the parent diamine after reductive cleavage, at a reporting limit of 5 mg·kg⁻¹. The dye powder is formulated as a 20 % paste in propylene glycol methyl ether acetate for ink‑jet deposition in LCD colour‑filter arrays, with a particle size D99 ≤ 0.8 µm as verified by a Hegman grind gauge.